Neoplasms
Conditions
Keywords
Cancer-Advanced Solid Tumors
Brief summary
The purpose of this study is to determine the safety and tolerability of an oral Farnesyl Protein Transferase Inhibitor (SCH 66336) when given in combination with intravenous docetaxel in cancer patients with advanced solid tumors.
Interventions
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Inclusion: * Male or Female * Measurable or evaluable disease * No more than 2 prior chemotherapy regimens. * Age greater than or equal to 18. * Karnofsky Performance Status greater than or equal to 70%. * Meets protocol requirements for specified laboratory values. * No manifestations of a malabsorption syndrome. * Written informed consent and cooperation of patient * Appropriate use of effective contraception if of child-bearing potential. Exclusion: * Acute or chronic leukemia or multiple myeloma. * Evidence of 2 or more active malignancies, expect for in situ or adequately treated basal or squamous cell skin cancer.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse Events | — |
| Laboratory Tests | — |
| ECG | — |
Secondary
| Measure | Time frame |
|---|---|
| Physical Exam | — |
| Pharmacokinetics | — |
| Tumor Response | — |
Outcome results
None listed